Recently Released Market Study: Half Year 2012: Big Pharma Update
The Big Pharma Peer set - comprising those companies with annual revenues in excess of $10bn - posted H1 2012 sales of $196.6bn, down by $4.2bn over the total for H1 2011. Of the 12 companies covered in this analysis, half posted positive H1 2012 sales growth (over H1 2011) others were not so fortunate.
View full press release